The Vaccine & Gene Therapy Institute of Florida (VGTI-FL) announced today that it has selected Mel Rothberg to become its new Chief Operating Officer (COO). Mel Rothberg has participated over the last 35 years in the development of the South Florida bio-science industry and is presently co-Chairman of Bio Florida’s Southeast Chapter. He has held executive positions in the medical device, information technology, bio-pharmaceutical and healthcare sectors.
Mark B. Williams, VGTI-FL’s current interim COO, said: “I am pleased to announce that we have selected a new permanent Chief Operating Officer for VGTI-Florida. Mel will join us initially as our Deputy Chief Operating Officer, and, after a transition period, will become our Chief Operating Officer effective July 1, 2012. Mel brings a wealth of business experience both inside and outside the bio-science world. Additionally, Mel is well known and established in Florida in the bio-science community, with contacts that we believe will be very beneficial to VGTI-Florida and our mission.”
Dr. Daniel M. Dorsa, President of VGTI-Florida noted that “Mel will be a significant addition to our strong scientific and support organization in Florida. He will be instrumental in leading the team we have assembled to ensure that we can continue our research efforts in addressing chronic infectious diseases, cancer and ailments that disproportionately affect aging populations.”
Mel commented that “I look forward to joining VGTI-Florida and working with its talented scientific and administrative staff. I have been involved in the development of the life science industry in South Florida for quite a few years and see VGTI-Florida as a major contributor to the growth of the bio-science industry throughout Florida. The Treasure Coast has been especially cognizant of the great promise of the bio-science industry and I look forward to working with the VGTI-Florida team in nurturing our efforts to recognize and appreciate the community’s commitment and support.”